Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Janzon

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Lakartidningen|July 15, 2015
[The truth about the clinical reality is in the registries. A register-based randomized clinical trial could provide representative picture]Tomas Jernberg, Magnus Janzon
Expert Review of Pharmacoeconomics & Outcomes Research|February 14, 2013
Cost-effectiveness of ticagrelor in acute coronary syndromesMartin Henriksson, Magnus Janzon
Scandinavian Cardiovascular Journal : SCJ|May 23, 2013
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarctionUlf Berglund, Lennart Nilsson, Magnus Janzon
American Heart Journal|June 25, 2004
Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trialMagnus Janzon, Lars-Ake Levin, Eva Swahn
International Journal of Health Policy and Management|November 15, 2014
Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in SwedenNathalie Eckard, Magnus Janzon, Lars-Åke Levin
International Journal of Health Policy and Management|September 5, 2015
Including Both Costs and Effects--The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent CommentariesNathalie Eckard, Magnus Janzon, Lars-Åke Levin
Scandinavian Cardiovascular Journal : SCJ|February 19, 2011
Compilation of cost-effectiveness evidence for different heart conditions and treatment strategiesNathalie Eckard, Magnus Janzon, Lars-Åke Levin
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 6, 2020
Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation InitiativesKasper Johannesen, Magnus Janzon, Tomas Jernberg, et al.
Pacing and Clinical Electrophysiology : PACE|August 26, 2009
Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry tachycardia in a Swedish population: consequences on health-related quality of lifeUlla Walfridsson, Anna Strömberg, Magnus Janzon, et al.
Journal of Atrial Fibrillation|May 13, 2017
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial FibrillationThomas Davidson, Magnus Husberg, Magnus Janzon, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Lakartidningen|July 15, 2015
[The truth about the clinical reality is in the registries. A register-based randomized clinical trial could provide representative picture]Tomas Jernberg, Magnus Janzon
Expert Review of Pharmacoeconomics & Outcomes Research|February 14, 2013
Cost-effectiveness of ticagrelor in acute coronary syndromesMartin Henriksson, Magnus Janzon
Scandinavian Cardiovascular Journal : SCJ|May 23, 2013
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarctionUlf Berglund, Lennart Nilsson, Magnus Janzon
American Heart Journal|June 25, 2004
Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trialMagnus Janzon, Lars-Ake Levin, Eva Swahn
International Journal of Health Policy and Management|November 15, 2014
Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in SwedenNathalie Eckard, Magnus Janzon, Lars-Åke Levin
International Journal of Health Policy and Management|September 5, 2015
Including Both Costs and Effects--The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent CommentariesNathalie Eckard, Magnus Janzon, Lars-Åke Levin
Scandinavian Cardiovascular Journal : SCJ|February 19, 2011
Compilation of cost-effectiveness evidence for different heart conditions and treatment strategiesNathalie Eckard, Magnus Janzon, Lars-Åke Levin
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 6, 2020
Subcategorizing the Expected Value of Perfect Implementation to Identify When and Where to Invest in Implementation InitiativesKasper Johannesen, Magnus Janzon, Tomas Jernberg, et al.
Pacing and Clinical Electrophysiology : PACE|August 26, 2009
Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry tachycardia in a Swedish population: consequences on health-related quality of lifeUlla Walfridsson, Anna Strömberg, Magnus Janzon, et al.
Journal of Atrial Fibrillation|May 13, 2017
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial FibrillationThomas Davidson, Magnus Husberg, Magnus Janzon, et al.
Pageof 8